Enliven Therapeutics Inc (ELVN)
$28.7
Live
Performance
- $28.39$29.11$28.70
1.08%
Downside
Day's Volatility :2.47%
Upside
1.41%
- $9.80$30.03$28.70
65.85%
Downside
52 Weeks Volatility :67.37%
Upside
4.43%
Returns
| Period | Enliven Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 24.04% | 0.0% |
6 Months | 64.59% | 0.0% |
1 Year | 126.56% | 0.0% |
3 Years | 22.11% | -23.0% |
Highlights
Market Capitalization | 1.3B |
Book Value | $6.46 |
Earnings Per Share (EPS) | -1.91 |
Wall Street Target Price | 35.6 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.55% |
Return On Equity TTM | -28.37% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -96.0M |
Diluted Eps TTM | -1.91 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.94 |
EPS Estimate Next Year | -2.47 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | -0.6 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 24.04%
Technicals Summary
Sell
Neutral
Buy
Enliven Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Enliven Therapeutics Inc | 23.04% | 64.59% | 126.56% | 22.11% | 22.11% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics Inc | NA | NA | NA | -1.94 | -0.28 | -0.2 | NA | 6.46 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Enliven Therapeutics Inc | Buy | $1.3B | 22.11% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Company Information
enliven therapeutics focuses on the discovery and development of next generation small molecule treatments for cancer. we are backed by top-tier life science venture funds. we seek experienced and passionate drug hunters to join our team as we grow our r&d organization in boulder, co.
Organization | Enliven Therapeutics Inc |
Employees | 52 |
CEO | Mr. Samuel S. Kintz M.B.A. |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$28.70
-1.03%
Invesco Bulletshares 2025 Hi
$28.70
-1.03%
Schwab International Dividend Equity Etf
$28.70
-1.03%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$28.70
-1.03%
Lightpath Technologies Inc
$28.70
-1.03%
Vaneck Vectors Global Alternative Energy Etf
$28.70
-1.03%
First Trust Flexible Municipal High Income Etf
$28.70
-1.03%
Drx Dly Reg Bank Bull 3x
$28.70
-1.03%
Graniteshares 2x Long Pltr Daily Etf
$28.70
-1.03%